We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
(+29%)
Cap. Flow
+$32.2M
Cap. Flow
% of AUM
1.94%
Top 10 Holdings %
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
2.8
quarters
Top 20 Avg Time Held Equity + Options
3
quarters
Avg Time Held Equity only
2.2
quarters
Top 10 Avg Time Held Equity only
2.9
quarters
Top 20 Avg Time Held Equity only
3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$23.8M |
| 2 |
Viatris
VTRS
|
+$14.8M |
| 3 |
Eagle Pharmaceuticals, Inc.
EGRX
|
+$14.4M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$12.4M |
| 5 |
NEVRO CORP.
NVRO
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$19.4M |
| 2 |
bluebird bio
BLUE
|
+$16.3M |
| 3 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$12.1M |
| 4 |
uniQure
QURE
|
+$11.1M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.96% |
| 2 | Miscellaneous | 17.3% |
| 3 | Consumer Staples | 0.52% |
| 4 | Financials | 0.09% |
| 5 | Technology | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Cigna
CI
$74.9B
| $3.56M | 0.21% |
21,970
+20,000
| +1,015% | +$2.76M |
2014 Q4
2 quarters
|
|
77
DELISTED
Catalyst Pharmaceutical
CPRX
| $3.52M | 0.21% |
851,200
-348,800
| -29% | -$1.39M |
2015 Q1
1 quarter
|
|
78
PUT
Travere Therapeutics
TVTX
$4.9B
| $3.31M | 0.2% |
+100,000
| New | +$2.74M |
2015 Q2
0 quarters
|
|
79
PUT
ProShares Ultra S&P500
SSO
$9.09B
| $3.23M | 0.19% |
+400,000
| New | +$3.35M |
2015 Q2
0 quarters
|
|
|
NDRM
80
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $3.07M | 0.18% |
200,000
-150,000
| -43% | -$2.11M |
2014 Q4
2 quarters
|
|
81
Evolent Health
EVH
$481M
| $2.98M | 0.18% |
+152,800
| New | +$2.85M |
2015 Q2
0 quarters
|
|
82
DELISTED
Walgreens Boots Alliance
WBA
| $2.98M | 0.18% |
35,292
+15,000
| +74% | +$1.29M |
2013 Q3
7 quarters
|
|
83
MacroGenics
MGNX
$237M
| $2.89M | 0.17% |
76,208
-30,000
| -28% | -$986K |
2013 Q4
6 quarters
|
|
84
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $2.85M | 0.17% |
465,225
-174,000
| -27% | -$1.35M |
2013 Q2
8 quarters
|
|
|
IMMU
85
PUT
DELISTED
Immunomedics Inc
IMMU
| $2.84M | 0.17% |
700,000
+100,000
| +17% | +$409K |
2015 Q1
1 quarter
|
|
86
Corbus Pharmaceuticals
CRBP
$102M
| $2.68M | 0.16% |
+29,000
| New | +$2.92M |
2015 Q2
0 quarters
|
|
87
DELISTED
Dermira, Inc.
DERM
| $2.67M | 0.16% |
152,000
| – | – |
2014 Q4
2 quarters
|
|
88
Xenon Pharmaceuticals
XENE
$3.47B
| $2.59M | 0.16% |
225,000
| – | – |
2014 Q4
2 quarters
|
|
|
IMMU
89
DELISTED
Immunomedics Inc
IMMU
| $2.44M | 0.15% |
+600,000
| New | +$2.45M |
2015 Q2
0 quarters
|
|
90
Abeona Therapeutics
ABEO
$280M
| $2.38M | 0.14% |
18,800
-31,200
| -62% | -$4.69M |
2014 Q4
2 quarters
|
|
|
NVTA
91
DELISTED
Invitae Corporation
NVTA
| $2.31M | 0.14% |
299,583
+134,583
| +82% | +$1.91M |
2015 Q1
1 quarter
|
|
92
DELISTED
iShares Currency Hedged MSCI Germany ETF
HEWG
| $2.27M | 0.14% |
87,000
+2,000
| +2% | +$55.2K |
2015 Q1
1 quarter
|
|
93
Invesco DB US Dollar Index Bullish Fund
UUP
$463M
| $2.25M | 0.14% |
+90,000
| New | +$2.27M |
2015 Q2
0 quarters
|
|
|
94
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
| $2.25M | 0.14% |
+1,250,000
| New | +$2.79M |
2015 Q2
0 quarters
|
|
95
PUT
DELISTED
Regulus Therapeutics
RGLS
| $2.2M | 0.13% |
+1,667
| New | +$2.69M |
2015 Q2
0 quarters
|
|
|
VTAE
96
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $2.16M | 0.13% |
+150,000
| New | +$2.04M |
2015 Q2
0 quarters
|
|
97
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $2.11M | 0.13% |
3,333
| – | – |
2014 Q4
2 quarters
|
|
98
Seres Therapeutics
MCRB
$26.9M
| $2.08M | 0.13% |
+2,500
| New | +$2.18M |
2015 Q2
0 quarters
|
|
|
99
ProShares Ultra S&P500
SSO
$9.09B
| $1.94M | 0.12% |
+240,000
| New | +$2.01M |
2015 Q2
0 quarters
|
|
100
Vericel Corp
VCEL
$2.08B
| $1.89M | 0.11% |
528,697
-60,600
| -10% | -$208K |
2014 Q3
3 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors's Q2 2015 filing shows 55 new, 41 increased, 36 reduced and 38 closed positions. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M. The largest sale was Neurocrine Biosciences, an estimated $19.4M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
- Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
- Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
- Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
- Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
- Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.
Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.